Mitigating Vasomotor Symptoms from Adjuvant Endocrine Therapy

Vasomotor symptoms — hot flashes and night sweats — are commonly reported by patients, both men and women, who receive adjuvant endocrine therapy for early-stage breast cancer. In many cases, these symptoms significantly impact quality of life, leading to nonadherence, noncompliance, and early discontinuation of therapy. Most of the numerous strategies for mitigating vasomotor symptoms, including low-dose antidepressants, acupuncture, and herbal products, have limited to no efficacy.

Q-122 is a nonhormonal, orally available compound that is postulated to affect activation of specific estrogen-responsive neurons in the hypothalamus responsible for vasomotor symptoms. Investigators conducted an industry-funded, multinational, double-blind, ran…